Nesta página
01ACAD preço
02Instantâneo
03Gráfico
05Sobre
06Desempenho
07Avaliação e rácios
14Lucros
15Fundamentos Completos
16Demonstrações
17Investidores institucionais (13F)
18Ativistas e proprietários de 5%+
19Executivos da empresa
20Participação em ETFs
21Consenso
22Pares
23Notícias
25Sinais de trading
26Minhas Métricas
ACAD ACADIA Pharmaceuticals Inc. - Common Stock
NASDAQ · Biotechnology · Ver em SEC EDGAR ↗ fechar Out 2, 2026 10-K/10-Q Ago 5, 2026
$19,95
· % da faixa de 52 semanas
· acima do mínimo
· para alta
$19,59mínima 52 sem
$30,96máxima 52 sem
Capitalização de Mercado (MRQ)
$3.43B
P/E (TTM)
8.9
EPS (TTM)
$2.23
Receita (TTM)
$1.14B
seus distintivos
Intervalo 52 Semanas
$20–$31
Classificação do Analista
BUY
Preço-Alvo
$32
P/E
8.9
ROE
35.7%
Margem de Lucro Líquido
33.4%
Sua barra de distintivos está vazia — fixe uma métrica em qualquer lugar desta página.
ACAD Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$19.95
Capitalização de Mercado (MRQ)
$3.43B
P/E (TTM)
8.9
EPS (TTM)
$2.23
Receita (TTM)
$1.14B
ROE (TTM)
35.7%
Intervalo 52 Semanas
$20–$31
ACAD Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
intervalo
barras
A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.
Sobre ACADIA Pharmaceuticals Inc. - Common Stock Visão geral da empresa da Wikipedia
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Product development
Nuplazid, a drug developed by Acadia in the late 1990s, "was designed to stimulate a subset of the brain’s serotonin receptors, or the proteins that govern memory, cognition and learning." On April 29, 2016, the FDA approved Acadia's drug, Nuplazid, for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. Nuplazid is the trade name for Acadia's proprietary molecule, pimavanserin, a selective serotonin inverse agonist preferentially targeting 5-HT2a receptors. Acadia had partnered with Biovail in the late-stage clinical testing of the drug, which showed trial failures as of 2009.
Acadia is running multiple Phase 2 and Phase 3 trials with pimavanserin in several central nervous system conditions: dementia-related psychosis, major depressive disorder, schizophrenia inadequate response, and schizophrenia negative symptoms.
As of 1997, Acadia was among several companies that licensed compounds from Genzyme's small-molecule compound library.
In 2023, the FDA approved trofinetide (marketed as Daybue) for use in Rett syndrome.
History
Acadia started in 1993 as Receptor Technologies, based in Winooski, Vermont. In 1997, the company relocated all operations and management from Vermont to San Diego, California, as a strategic move to garner partnerships with other biotechnology companies. However, the company also had an office in Denmark, in which it received a crucial part of its early investments from BankInvest, under managing director Florian Schönharting, Kommunernes Pensionsforsikring A/S and Dansk Kapitalanlæg Aktieselskab as well as private investor Lars Christiansen. At the time, the company had fifty employees, fourteen of whom were in the Denmark office. The focus of the company in its early years was on genetic screens for receptors, aiming to accelerate early stage drug discovery.
The company planned to conduct an initial public offering (IPO) consisting of 31.6% of the company in 2001, with the intention of raising US$64 million and listing on the NASDAQ exchange under the symbol ACAD. At the time, Acadia and Allergan were collaborating on development of a treatment for glaucoma, and Allergan would retain a 6.3% ownership stake in Acadia after the IPO. However, the company's IPO, which ultimately took place in May 2004, did not fare as well as expected and netted only US$35 million. At the time, the company had five drugs in development and was running two in human trials. The company had a subsequent round of stock offering in May 2007 which raised US$102 million.
In September 2020, Acadia Pharmaceuticals acquired clinical-stage biotechnology company CerSci Therapeutics.
Corporate governance
In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.
== References ==
Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗
setorHealthcare
indústriaBiotechnology
funcionários796
paísUS
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita$1.07B2016-12-31 → 2025-12-31
EPS$2.302020-12-31 → 2025-12-31
Fluxo de caixa livre$105M2016-12-31 → 2025-12-31
Margem líquida33.4%2016-12-31 → 2025-12-31
Avaliação e Proporções
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
| Métrica | Tendência de 5 anos | ACAD | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| P/E (TTM) | 8.9média 5A ≈-18.7 | ≈-18.7 | 13.8 | Subvalorizado | |
| P/S (TTM) | 3.0média 5A ≈5.5 | ≈5.5 | 11.9 | Subvalorizado | |
| P/B (MRQ) | 2.6média 5A ≈6.6 | ≈6.6 | 3.4 | Subvalorizado | |
| Preço / FCF (TTM) | 23.6média 5A ≈64.0 | ≈64.0 | · | · | |
| Preço / Fluxo de Caixa (TTM) | 21.4média 5A ≈63.4 | ≈63.4 | · | · | |
| Preço / Valor Patrimonial Tangível (MRQ) | 2.9média 5A ≈7.3 | ≈7.3 | · | · |
A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
| Métrica | Tendência de 5 anos | ACAD | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Margem Operacional (TTM) | 7.6%média 5A ≈-10.9% | ≈-10.9% | 12.5% | Em linha | |
| EBITDA Margin (Margem EBITDA) | 9.8%média 5A ≈-10.9% | ≈-10.9% | 12.5% | Em linha | |
| Margem de Impostos Pré-Tributação (TTM) | 10.7%média 5A ≈-8.6% | ≈-8.6% | 16.4% | Em linha | |
| Margem de Lucro Líquido (TTM) | 33.4%média 5A ≈-4.9% | ≈-4.9% | 10.2% | Em linha | |
| ROA (TTM) | 25.6%média 5A ≈-2.7% | ≈-2.7% | -7.4% | Primeira linha | |
| ROE (TTM) | 35.7%média 5A ≈-5.1% | ≈-5.1% | -10.7% | Primeira linha | |
| ROIC | 24.0%média 5A ≈-11.4% | ≈-11.4% | -3.0% | Primeira linha |
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
| Métrica | Tendência de 5 anos | ACAD | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Índice de liquidez corrente (MRQ) | 3.4média 5A ≈3.8 | ≈3.8 | 6.5 | Baixa liquidez | |
| Quick Ratio (Índice de Liquidez Seca) | 1.1média 5A ≈1.4 | ≈1.4 | 5.0 | Baixa liquidez |
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
| Métrica | Tendência de 5 anos | ACAD | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Revenue YoY (Receita Ano a Ano) | 11.9%média 5A ≈20.1% | ≈20.1% | · | · | |
| Revenue CAGR 3Y (CAGR Receita 3A) | 27.5%média 5A ≈23.7% | ≈23.7% | · | · | |
| Revenue CAGR 5Y (CAGR Receita 5A) | 19.4% | · | · | · | |
| EPS YoY | 69.1% | · | · | · | |
| Net Income YoY (Lucro Líquido Ano a Ano) | 72.7% | · | · | · |
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
| Métrica | Tendência de 5 anos | ACAD | média 5A | Mediana de Pares | Veredito |
|---|---|---|---|---|---|
| Asset Turnover (Giro do Ativo) | 0.8média 5A ≈0.9 | ≈0.9 | 0.4 | Primeira linha | |
| Inventory Turnover (Giro de Estoque) | 0.9média 5A ≈1.1 | ≈1.1 | · | · | |
| Receivables Turnover (Giro de Contas a Receber) | 9.7média 5A ≈9.1 | ≈9.1 | 10.5 | Em linha | |
| Revenue / Employee (Receita anual ÷ funcionários (número de funcionários reportado, yfinance). Derivado — não é um conceito SEC-XBRL armazenado.) | ≈$1.3M | · | · | · |
valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
228.8%
Próximo relatório
Nov 03, 2026
| Período | Relatório | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|---|
| 30 de Junho de 2026 | Ago 11, 2026 | $0.18 | $0.06 | 207.2% |
| 31 de Março de 2026 | Mai 13, 2026 | $0.02 | $0.06 | -68.4% |
| 31 de Dezembro de 2025 | $1.60 | $0.14 | 1044.5% | |
| 30 de Setembro de 2025 | $0.42 | $0.15 | 178.1% | |
| 30 de Junho de 2025 | $0.16 | $0.14 | 14.4% | |
| 31 de Março de 2025 | $0.11 | $0.11 | -3.2% |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Cost of Revenue | $89M | $82M | $42M | $10M | $19M | $10M | $11M | $12M | $9M | $3M | · | · | |
| Gross Profit | · | · | $685M | $507M | $473M | $432M | $328M | $211M | $116M | $14M | · | · | |
| R&D Expense | $329M | $303M | $352M | $362M | $239M | $319M | $240M | $187M | $149M | $99M | $74M | $61M | |
| SG&A Expense | $549M | $488M | $407M | $369M | $396M | $389M | $326M | $266M | $255M | $186M | $88M | $33M | |
| Operating Expenses | $967M | $727M | $800M | $741M | $655M | $728M | $586M | $471M | $417M | $290M | $165M | $93M | |
| Operating Income | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M | |
| Other Non-op | $2M | $2M | $5M | $4M | $2M | $-997.0K | $997.0K | $-2M | · | · | · | · | |
| Pretax Income | $139M | $258M | $-51M | $-213M | $-168M | $-281M | $-234M | $-244M | $-288M | $-270M | $-164M | $-92M | |
| Income Tax | $-252M | $32M | $10M | $3M | $351.0K | $611.0K | $876.0K | $1M | $1M | $1M | $330.0K | $0 | |
| Net Income | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| EPS (Basic) | $2.32 | $1.37 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| EPS (Diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · | |
| Shares (Basic) | 168,356,000 | 165,717,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| Shares (Diluted) | 169,919,000 | 166,362,000 | 163,819,000 | 161,683,000 | 160,493 | 157,331 | · | · | · | · | · | · | |
| EBITDA | $105M | $231M | $-73M | $-224M | $-170M | $-287M | $-247M | $-247M | $-292M | $-273M | $-165M | $-93M |
Balanço Patrimonial
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $178M | $320M | $189M | $115M | $147M | $326M | $190M | $135M | $69M | $164M | $102M | $62M | |
| Receivables | $121M | $99M | $98M | $62M | $64M | $48M | $36M | $26M | $17M | $6M | · | · | |
| Inventory | $111M | $92M | $40M | $12M | $14M | $10M | $6M | $4M | $5M | $4M | · | · | |
| Prepaid Expense | $60M | $56M | $39M | $21M | $24M | $26M | $19M | $21M | $8M | $8M | $2M | $1M | |
| Current Assets | $1.06B | $938M | $616M | $508M | $618M | $718M | $760M | $526M | $373M | $548M | $219M | $325M | |
| PP&E (Net) | $8M | $4M | $5M | $6M | $8M | $9M | $3M | $3M | $3M | $3M | $2M | $553.0K | |
| PP&E (Gross) | $17M | $14M | $14M | $14M | $14M | $13M | $9M | $8M | $7M | $6M | $5M | $3M | |
| Accum. Depreciation | $9M | $10M | $10M | $8M | $6M | $4M | $5M | $4M | $4M | $3M | $3M | $2M | |
| Intangibles | $109M | $120M | $65M | $0 | $0 | $1M | $3M | $4M | $6M | $7M | · | · | |
| Other Non-current Assets | $4M | $359.0K | $476.0K | $8M | $4M | $2M | $3M | $2M | $354.0K | $785.0K | $329.0K | $287.0K | |
| Total Assets | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Accounts Payable | $11M | $16M | $18M | $13M | $7M | $8M | $7M | $3M | $9M | $4M | $2M | $2M | |
| Accrued Liabilities | $266M | $379M | $237M | $113M | $89M | $97M | $68M | $56M | $40M | $36M | $20M | $14M | |
| Current Liabilities | $277M | $395M | $254M | $126M | $96M | $106M | $75M | $60M | $49M | $43M | $22M | $16M | |
| Capital Leases | $41M | $42M | $48M | $53M | $56M | $44M | $6M | · | · | · | · | · | |
| Deferred Tax | $11M | $11M | $12M | $13M | $14M | $13M | $3M | · | · | · | · | · | |
| Other Non-current Liabilities | $19M | $18M | $15M | $9M | $7M | $5M | $3M | $2M | · | · | · | · | |
| Total Liabilities | $337M | $455M | $317M | $187M | $159M | $156M | $84M | $61M | $49M | $43M | $22M | $16M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $15.0K | $14.0K | $12.0K | $12.0K | $10.0K | $10.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | $1.45B | $862M | $808M | |
| Retained Earnings | $-1.81B | $-2.20B | $-2.43B | $-2.37B | $-2.15B | $-1.99B | $-1.70B | $-1.47B | $-1.22B | $-934M | $-663M | $-498M | |
| AOCI | $1M | $292.0K | $24.0K | $-975.0K | $-192.0K | $36.0K | $297.0K | $-372.0K | $-399.0K | $106.0K | $11.0K | $-9.0K | |
| Stockholders' Equity | $1.23B | $733M | $432M | $400M | $541M | $627M | $699M | $479M | $335M | $518M | $200M | $309M | |
| Liabilities + Equity | $1.56B | $1.19B | $749M | $588M | $700M | $783M | $783M | $540M | $385M | $561M | $222M | $325M | |
| Shares Outstanding | 170,309,376 | 166,708,856 | 164,650,219 | 162,064,872 | 161,012,695 | 159,637,771 | 155,275,300 | 143,853,597 | 124,410,552 | 121,367,169 | 101,938,702 | 100,047,331 |
Fluxo de Caixa
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | · | $206.0K | |
| Stock-based Comp | $52M | $67M | $66M | $68M | $64M | $84M | $82M | $82M | $76M | $55M | $40M | $16M | |
| Deferred Tax | $-250M | $0 | $0 | $3M | $351.0K | · | · | · | · | · | · | · | |
| Amort. of Intangibles | $11M | $15M | $4M | $0 | $1M | $1M | $1M | $1M | $1M | $985.0K | $0 | $0 | |
| Operating Cash Flow | $110M | $158M | $17M | $-114M | $-126M | $-136M | $-151M | $-167M | $-218M | $-208M | $-122M | $-66M | |
| CapEx | $5M | $523.0K | $50.0K | $0 | $1M | $8M | $1M | $2M | $812.0K | $2M | $2M | $180.0K | |
| Investing Cash Flow | $-303M | $-31M | $32M | $73M | $-71M | $193M | $-166M | $-71M | $92M | $-262M | · | · | |
| Stock Issued | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Net Stock Activity | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $519M | $15M | $204M | |
| Financing Cash Flow | $50M | $7M | $25M | $8M | $18M | $81M | $372M | $307M | $31M | $534M | · | · | |
| Net Change in Cash | $-143M | $134M | $74M | $-33M | $-179M | $137M | $55M | $68M | $-94M | $63M | $40M | $50M | |
| Taxes Paid | $25M | $20M | $6M | $2M | $1M | $1M | $2M | $1M | $1M | $-365.0K | $415.0K | · | |
| Free Cash Flow | $105M | $157M | $17M | $-114M | $-127M | $-144M | $-152M | $-170M | $-219M | $-212M | $-124M | $-67M |
Lucratividade
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | 94.3% | 98.0% | 97.8% | 97.7% | 96.7% | 94.5% | 92.7% | 82.2% | · | · | |
| Operating Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| Net Margin | 36.5% | 23.6% | -8.4% | -41.8% | -34.7% | -63.7% | -69.4% | -109.6% | -231.7% | -1565.9% | -269578.7% | -77062.5% | |
| Pretax Margin | 13.0% | 26.9% | -7.0% | -41.3% | -34.6% | -63.6% | -69.1% | -109.0% | -230.8% | -1558.2% | -269037.7% | · | |
| EBITDA Margin | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% | -64.9% | -72.7% | -110.6% | -234.1% | -1574.1% | -269855.7% | -77691.7% | |
| ROA | 28.4% | 23.4% | -9.2% | -33.5% | -22.6% | -36.0% | -35.5% | -53.0% | -61.2% | -69.3% | -60.1% | -35.9% | |
| ROE | 38.1% | 34.6% | -15.4% | -52.3% | -30.3% | -43.9% | -33.9% | -69.8% | -67.8% | -75.6% | -64.6% | -37.6% | |
| ROIC | 24.0% | 27.6% | -20.4% | -56.5% | -31.6% | -45.8% | -35.4% | -51.9% | -87.5% | -52.9% | -82.6% | · |
Liquidez e Solvência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 | 6.8 | 10.2 | 8.8 | 7.6 | 12.9 | 10.0 | 20.5 | |
| Quick Ratio | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 | 3.5 | 3.0 | 2.7 | 1.8 | 4.0 | 4.7 | 3.9 |
Eficiência
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 1.0 | 1.1 | 0.8 | 0.7 | 0.6 | 0.5 | 0.5 | 0.3 | 0.0 | 0.0 | 0.0 | |
| Inventory Turnover | 0.9 | 1.2 | 1.6 | 0.8 | 0.9 | 1.3 | 2.2 | · | 1.9 | 1.5 | · | · | |
| Receivables Turnover | 9.7 | 9.7 | 9.1 | 8.2 | 8.6 | 10.5 | 11.0 | 10.3 | 10.7 | 5.9 | · | · |
Por Ação
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.21 | $4.40 | $2.62 | $2.47 | $3.36 | $3.93 | $4.50 | $3.33 | $2.69 | $4.27 | $1.96 | $3.09 | |
| Revenue / Share | $6.31 | $5.76 | $4434.39 | $3199.07 | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $0.65 | $0.95 | $101.95 | $-705.30 | · | · | · | · | · | · | · | · | |
| Cash / Share | $1.04 | $1.92 | $1.15 | $0.71 | $0.92 | $2.04 | $1.22 | $0.94 | $0.56 | $1.35 | $1.00 | $0.62 | |
| EPS (TTM) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | · | · | · | · | · | · |
Taxas de Crescimento
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.9% | 31.9% | 40.5% | 6.8% | 9.6% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 27.5% | 25.5% | 18.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 19.4% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 69.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 72.7% | · | · | · | · | · | · | · | · | · | · | · |
Avaliação (TTM)
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.07B | $958M | $726M | $517M | $484M | $442M | $339M | $224M | $125M | $17M | $61.0K | $120.0K | |
| Net Income TTM | $391M | $226M | $-61M | $-216M | $-168M | $-282M | $-235M | $-245M | $-289M | $-271M | $-164M | $-92M | |
| Market Cap | $4.55B | $3.06B | $5.16B | $2.58B | $3.76B | $8.53B | $6.64B | $2.33B | $3.75B | $3.50B | $3.63B | $3.18B | |
| P/E | 11.6 | 13.5 | -84.6 | -11.9 | -22.2 | -29.9 | · | · | · | · | · | · | |
| P/S | 4.2 | 3.2 | 7.1 | 5.0 | 7.8 | 19.3 | 19.6 | 10.4 | 30.0 | 202.0 | 59575.7 | 26470.9 | |
| P/B | 3.7 | 4.2 | 11.9 | 6.4 | 6.9 | 13.6 | 9.5 | 4.9 | 11.2 | 6.8 | 18.2 | 10.3 | |
| P / Tangible Book | 4.1 | 5.0 | 14.1 | 6.4 | 6.9 | 13.6 | · | · | · | · | · | · | |
| P / Cash Flow | 41.4 | 19.4 | 308.7 | -22.6 | -29.9 | -62.7 | -44.0 | -13.9 | -17.2 | -16.6 | -29.8 | -47.8 | |
| P / FCF | 43.3 | 19.5 | 309.6 | -22.6 | -29.6 | -59.4 | -43.6 | -13.7 | -17.1 | -16.5 | -29.3 | -47.7 | |
| Earnings Yield | 8.6% | 7.4% | -1.2% | -8.4% | -4.5% | -3.4% | · | · | · | · | · | · |
Demonstração de Resultados
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $308M | $268M | $284M | $279M | $265M | $244M | $260M | $250M | $242M | $206M | $231M | $212M | $165M | $118M | $136M | $131M | |
| Cost of Revenue | $28M | $25M | $26M | $22M | $21M | $20M | $22M | $19M | $18M | $23M | $18M | $15M | $7M | $2M | $2M | $2M | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | $213M | $197M | $158M | $117M | $134M | $129M | |
| R&D Expense | $82M | $77M | $85M | $88M | $78M | $78M | $101M | $67M | $76M | $60M | $67M | $157M | $59M | $69M | $76M | $81M | |
| SG&A Expense | $160M | $171M | $156M | $133M | $134M | $126M | $130M | $133M | $117M | $108M | $111M | $98M | $96M | $101M | $104M | $78M | |
| Operating Expenses | $270M | $273M | $267M | $243M | $232M | $225M | $106M | $219M | $212M | $191M | $196M | $269M | $162M | $172M | $183M | $162M | |
| Operating Income | $38M | $-5M | $17M | $36M | $32M | $19M | $154M | $32M | $30M | $15M | $35M | $-58M | $3M | $-54M | $-46M | $-31M | |
| Other Non-op | $647.0K | $542.0K | $596.0K | $593.0K | $594.0K | $588.0K | $575.0K | $576.0K | $386.0K | $286.0K | $0 | $2M | $-1M | $5M | $2M | $2M | |
| Pretax Income | $46M | $4M | $26M | $45M | $40M | $28M | $161M | $39M | $37M | $21M | $40M | $-52M | $6M | $-45M | $-41M | $-26M | |
| Income Tax | $15M | $344.0K | $-247M | $-27M | $14M | $9M | $17M | $6M | $4M | $4M | $-6M | $13M | $5M | $-2M | $835.0K | $768.0K | |
| Net Income | $32M | $4M | $274M | $72M | $27M | $19M | $144M | $33M | $33M | $17M | $46M | $-65M | $1M | $-43M | $-42M | $-27M | |
| EPS (Basic) | $0.18 | $0.02 | $1.62 | $0.43 | $0.16 | $0.11 | $0.87 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| EPS (Diluted) | $0.18 | $0.02 | $1.61 | $0.42 | $0.16 | $0.11 | $0.86 | $0.20 | $0.20 | $0.10 | $0.29 | $-0.40 | $0.01 | $-0.27 | $-0.26 | $-0.17 | |
| Shares (Basic) | 171,603,000 | 170,517,000 | · | 168,836,000 | 167,827,000 | 166,808,000 | · | 165,974,000 | 165,551,000 | 164,798,000 | · | 164,234,000 | 163,458,000 | 162,263,000 | · | 161,852 | |
| Shares (Diluted) | 172,851,000 | 172,706,000 | · | 170,650,000 | 168,681,000 | 167,668,000 | · | 166,178,000 | 166,174,000 | 166,623,000 | · | 164,234,000 | 165,046,000 | 162,263,000 | · | 161,852 | |
| EBITDA | $38M | $-5M | · | $36M | $32M | $19M | · | $32M | $30M | $15M | · | $-58M | $3M | $-54M | · | $-31M |
Balanço Patrimonial
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $385M | $282M | $178M | $258M | $254M | $218M | $320M | $155M | $177M | $205M | $189M | $98M | $108M | $291M | $115M | $155M | |
| Receivables | $151M | $135M | $121M | $116M | $108M | $106M | $99M | $98M | $104M | $95M | · | $93M | $82M | $66M | · | $56M | |
| Inventory | $109M | $112M | $111M | $106M | $111M | $103M | $92M | $87M | $86M | $67M | · | $25M | $14M | $11M | · | $12M | |
| Prepaid Expense | $69M | $65M | $60M | $61M | $53M | $53M | $56M | $52M | $46M | $43M | · | $38M | $24M | $24M | · | $23M | |
| Current Assets | $1.22B | $1.10B | $1.06B | $1.08B | $961M | $871M | $938M | $788M | $729M | $675M | · | $499M | $493M | $503M | · | $522M | |
| PP&E (Net) | $17M | $15M | $8M | $4M | $4M | $3M | $4M | $4M | $4M | $4M | · | $5M | $5M | $6M | · | $7M | |
| PP&E (Gross) | · | · | $17M | · | · | · | $14M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $10M | · | · | · | · | · | · | · | · | · | |
| Intangibles | $103M | $106M | $109M | $112M | $114M | $117M | $120M | $106M | $108M | $110M | · | $67M | $68M | $70M | · | · | |
| Other Non-current Assets | $4M | $4M | $4M | $3M | $2M | $1M | $359.0K | $359.0K | $476.0K | $476.0K | · | $475.0K | $11M | $12M | · | $6M | |
| Total Assets | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Accounts Payable | $45M | $12M | $11M | $22M | $20M | $18M | $16M | $19M | $20M | $19M | · | $12M | $19M | $17M | · | $10M | |
| Accrued Liabilities | $317M | $293M | $266M | $335M | $310M | $284M | $379M | $325M | $318M | $311M | · | $197M | $169M | $207M | · | $107M | |
| Current Liabilities | $361M | $306M | $277M | $357M | $330M | $303M | $395M | $344M | $338M | $331M | · | $210M | $188M | $224M | · | $117M | |
| Capital Leases | $60M | $39M | $41M | $43M | $45M | $45M | $42M | $40M | $47M | $49M | · | $48M | $50M | $51M | · | $54M | |
| Deferred Tax | · | · | $11M | · | · | · | $11M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $15M | $13M | $19M | $14M | $29M | $20M | $18M | $15M | $12M | $11M | · | $13M | $9M | $5M | · | $6M | |
| Total Liabilities | $436M | $357M | $337M | $413M | $403M | $367M | $455M | $400M | $397M | $391M | · | $270M | $247M | $281M | · | $177M | |
| Common Stock | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | $16.0K | · | $16.0K | $16.0K | $16.0K | · | $16.0K | |
| Retained Earnings | $-1.78B | $-1.81B | $-1.81B | $-2.09B | $-2.16B | $-2.19B | $-2.20B | $-2.35B | $-2.38B | $-2.41B | · | $-2.48B | $-2.41B | $-2.41B | · | $-2.33B | |
| AOCI | $-958.0K | $-563.0K | $1M | $989.0K | $406.0K | $437.0K | $292.0K | $858.0K | $-339.0K | $-229.0K | · | $-319.0K | $-535.0K | $-220.0K | · | $-1M | |
| Stockholders' Equity | $1.31B | $1.25B | $1.23B | $917M | $822M | $765M | $733M | $577M | $517M | $464M | $432M | $362M | $396M | $374M | $400M | $426M | |
| Liabilities + Equity | $1.74B | $1.61B | $1.56B | $1.33B | $1.23B | $1.13B | $1.19B | $977M | $914M | $855M | · | $633M | $643M | $655M | · | $602M | |
| Shares Outstanding | 172,132,442 | 171,086,205 | 170,309,376 | 169,146,043 | 168,607,881 | 167,116,045 | 166,708,856 | 166,351,715 | 165,853,301 | 164,959,736 | · | 163,968,949 | 163,355,787 | 162,384,178 | · | 161,871,806 |
Fluxo de Caixa
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $17M | $15M | $13M | $13M | $14M | $11M | $10M | $26M | $16M | $15M | $18M | $19M | $15M | $15M | $14M | $18M | |
| Amort. of Intangibles | $3M | $3M | $3M | $3M | $3M | $3M | $5M | $2M | $2M | $5M | $1M | $1M | $1M | $0 | $0 | $0 | |
| Operating Cash Flow | $101M | $34M | $-49M | $74M | $64M | $20M | $40M | $63M | $25M | $29M | $85M | $-59M | $8M | $-18M | $-24M | $-727.0K | |
| CapEx | $5M | $5M | $4M | $388.0K | $297.0K | $0 | $453.0K | $70.0K | · | · | $0 | · | · | · | $0 | $0 | |
| Investing Cash Flow | $-9M | $66M | $-56M | $-79M | $-43M | $-124M | $122M | $-82M | $-56M | $-14M | $-347.0K | $34M | $-194M | $193M | $-18M | $15M | |
| Stock Issued | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Stock Activity | · | $4M | · | · | · | $2M | · | · | · | $1M | · | · | · | $1M | · | · | |
| Financing Cash Flow | $10M | $4M | $23M | $9M | $16M | $2M | $2M | $268.0K | $4M | $1M | $5M | $13M | $5M | $1M | $2M | $287.0K | |
| Net Change in Cash | $103M | $105M | $-82M | $4M | $37M | $-102M | $164M | $-19M | $-28M | $16M | $90M | $-12M | $-181M | $176M | $-40M | $15M | |
| Free Cash Flow | · | $29M | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Lucratividade
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| Net Margin | 10.2% | 1.4% | · | 25.8% | 10.1% | 7.8% | · | 13.1% | 13.8% | 8.0% | · | -30.8% | 0.67% | -36.3% | · | -20.8% | |
| Pretax Margin | 15.1% | 1.5% | · | 16.0% | 15.2% | 11.4% | · | 15.5% | 15.4% | 10.2% | · | -24.6% | 3.8% | -37.9% | · | -20.2% | |
| EBITDA Margin | 12.3% | -1.7% | · | 12.8% | 12.2% | 7.9% | · | 12.6% | 12.6% | 7.4% | · | -27.3% | 1.8% | -45.2% | · | -23.6% | |
| ROA | 2.1% | 0.27% | · | 6.2% | 2.5% | 1.9% | · | 4.1% | 4.3% | 2.2% | · | -10.5% | 0.18% | -6.7% | · | -4.1% | |
| ROE | 3.0% | 0.36% | · | 9.6% | 4.0% | 3.1% | · | 7.0% | 7.3% | 4.0% | · | -16.6% | 0.27% | -10.5% | · | -5.5% | |
| ROIC | 2.0% | -0.34% | · | 6.3% | 2.6% | 1.7% | · | 4.6% | 5.3% | 2.6% | · | -19.9% | 0.13% | -13.7% | · | -7.5% |
Liquidez e Solvência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.6 | · | 3.0 | 2.9 | 2.9 | · | 2.3 | 2.2 | 2.0 | · | 2.4 | 2.6 | 2.2 | · | 4.5 | |
| Quick Ratio | 1.5 | 1.4 | · | 1.0 | 1.1 | 1.1 | · | 0.7 | 0.8 | 0.9 | · | 0.9 | 1.0 | 1.6 | · | 1.8 |
Eficiência
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.2 | · | 0.2 | |
| Inventory Turnover | 0.3 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.6 | · | 0.8 | 0.6 | 0.1 | · | 0.2 | |
| Receivables Turnover | 2.4 | 2.2 | · | 2.6 | 2.5 | 2.4 | · | 2.6 | 2.6 | 2.6 | · | 2.9 | 2.2 | 1.8 | · | 2.2 |
Por Ação
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $7.59 | $7.29 | · | $5.42 | $4.88 | $4.58 | · | $3.47 | $3.12 | $2.81 | · | $2.21 | $2.42 | $2.30 | · | $2.63 | |
| Revenue / Share | $1.78 | $1.55 | · | $1.63 | $1.57 | $1.46 | · | $1.51 | $1.46 | $1.24 | · | $1289.01 | $1001.15 | $0.73 | · | $807.61 | |
| Cash Flow / Share | · | $0.20 | · | · | · | $0.12 | · | · | · | $0.17 | · | · | · | $-0.11 | · | · | |
| Cash / Share | $2.24 | $1.65 | · | $1.53 | $1.50 | $1.30 | · | $0.93 | $1.07 | $1.24 | · | $0.60 | $0.66 | $1.79 | · | $0.96 | |
| EPS (TTM) | $2.23 | $2.21 | · | $1.55 | $1.33 | $1.37 | · | $0.79 | $0.19 | $0.00 | · | $-0.92 | $-0.69 | $-0.91 | · | $-1.35 |
Avaliação (TTM)
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $1.14B | $1.10B | · | $1.05B | $1.02B | $996M | · | $929M | $891M | $814M | · | $632M | $551M | $520M | · | $512M | |
| Net Income TTM | $380M | $376M | · | $261M | $222M | $229M | · | $129M | $31M | $-2M | · | $-149M | $-111M | $-146M | · | $-217M | |
| Market Cap | $4.35B | $3.81B | · | $3.61B | $3.64B | $2.78B | · | $2.56B | $2.70B | $3.05B | · | $3.42B | $3.91B | $3.06B | · | $2.65B | |
| P/E | 11.3 | 10.1 | · | 13.8 | 16.2 | 12.1 | · | 19.5 | 85.5 | · | · | -22.7 | -34.7 | -20.7 | · | -12.1 | |
| P/S | 3.8 | 3.5 | · | 3.4 | 3.6 | 2.8 | · | 2.8 | 3.0 | 3.7 | · | 5.4 | 7.1 | 5.9 | · | 5.2 | |
| P/B | 3.3 | 3.1 | · | 3.9 | 4.4 | 3.6 | · | 4.4 | 5.2 | 6.6 | · | 9.4 | 9.9 | 8.2 | · | 6.2 | |
| P / Tangible Book | 3.6 | 3.3 | · | 4.5 | 5.1 | 4.3 | · | 5.4 | 6.6 | 8.6 | · | 11.6 | 11.9 | 10.0 | · | 6.2 | |
| P / Cash Flow | · | 112.1 | · | · | · | 136.6 | · | · | · | 104.9 | · | · | · | -170.4 | · | · | |
| Earnings Yield | 8.8% | 9.9% | · | 7.3% | 6.2% | 8.2% | · | 5.1% | 1.2% | 0.00% | · | -4.4% | -2.9% | -4.8% | · | -8.2% |
Período mais recente à esquerda · valores nulos mostrados como ·
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Receita | $1.07B | $958M | $726M | $517M | $484M |
| Margem Bruta % | · | · | 94.3% | 98.0% | 97.8% |
| Margem Operacional % | 9.8% | 24.1% | -10.1% | -43.2% | -35.2% |
| Lucro líquido | $391M | $226M | $-61M | $-216M | $-168M |
| EPS Diluído | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Índice de liquidez corrente | 3.8 | 2.4 | 2.4 | 4.0 | 6.4 |
| Índice de Liquidez Seca | 1.1 | 1.1 | 1.1 | 1.4 | 2.2 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fluxo de caixa livre | $105M | $157M | $17M | $-114M | $-127M |
Investidores institucionais (13F) 386 declarantes · $4.7B total · Em 30 de Setembro de 2026
Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.
Detentores
386
Valor detido
$4.7B
Novas posições
49
Posições encerradas
36
Atividade institucional — Q2 2026 vs trimestre anterior
| Novas posições | Posições encerradas | Aumentou | Diminuído | Variação líquida de ações |
|---|---|---|---|---|
| 49 (-4 vs trimestre anterior) | 36 (+8 vs trimestre anterior) | 135 (+15 vs trimestre anterior) | 115 (-7 vs trimestre anterior) | +4.6M |
Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.
| Instituição | Valor | Ações | % de 13F rastreado | Tipo |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | $1.085.696.471 | 42.912.904 | 23,31% | Ações |
| BlackRock, Inc. | $569.633.876 | 22.515.173 | 12,23% | Ações |
| VANGUARD GROUP INC | $404.762.192 | 15.153.957 | 8,69% | Ações |
| STATE STREET CORP | $229.628.164 | 9.076.212 | 4,93% | Ações |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $223.612.785 | 8.838.450 | 4,80% | Ações |
| RTW INVESTMENTS, LP | $180.756.457 | 7.144.524 | 3,88% | Ações |
| VANGUARD CAPITAL MANAGEMENT LLC | $145.822.875 | 5.763.750 | 3,13% | Ações |
| DIMENSIONAL FUND ADVISORS LP | $93.482.749 | 3.694.988 | 2,01% | Ações |
| GEODE CAPITAL MANAGEMENT, LLC | $84.977.229 | 3.358.129 | 1,82% | Ações |
| Palo Alto Investors LP | $72.461.629 | 2.864.096 | 1,56% | Ações |
| GOLDMAN SACHS GROUP INC | $65.276.910 | 2.580.115 | 1,40% | Ações |
| Qube Research & Technologies Ltd | $61.899.233 | 2.446.610 | 1,33% | Ações |
| Point72 Asset Management, L.P. | $61.559.150 | 2.433.168 | 1,32% | Ações |
| CITADEL ADVISORS LLC | $55.209.078 | 2.182.177 | 1,19% | Ações |
| Pictet Asset Management Holding SA | $50.146.450 | 1.983.198 | 1,08% | Ações |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $49.826.959 | 1.969.445 | 1,07% | Ações |
| MARSHALL WACE, LLP | $44.650.402 | 1.764.838 | 0,96% | Ações |
| D. E. Shaw & Co., Inc. | $42.957.806 | 1.697.937 | 0,92% | Ações |
| BRAIDWELL LP | $41.653.895 | 1.646.399 | 0,89% | Ações |
| NORGES BANK | $41.069.692 | 1.623.308 | 0,88% | Ações |
| Frazier Life Sciences Management, L.P. | $36.386.409 | 1.438.198 | 0,78% | Ações |
| NORTHERN TRUST CORP | $34.595.776 | 1.367.422 | 0,74% | Ações |
| Nuveen, LLC | $34.109.259 | 1.348.192 | 0,73% | Ações |
| Artisan Partners Limited Partnership | $33.525.890 | 1.325.134 | 0,72% | Ações |
| BANK OF AMERICA CORP /DE/ | $32.899.740 | 1.300.385 | 0,71% | Ações |
| RENAISSANCE TECHNOLOGIES LLC | $32.449.679 | 1.282.596 | 0,70% | Ações |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $30.520.301 | 1.206.336 | 0,66% | Ações |
| Allspring Global Investments Holdings, LLC | $28.540.663 | 1.132.566 | 0,61% | Ações |
| Rockefeller Capital Management L.P. | $25.690.127 | 1.015.420 | 0,55% | Ações |
| MORGAN STANLEY | $23.949.976 | 946.639 | 0,51% | Ações |
| TWO SIGMA INVESTMENTS, LP | $23.452.898 | 926.992 | 0,50% | Ações |
| VANGUARD FIDUCIARY TRUST CO | $23.082.961 | 912.370 | 0,50% | Ações |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $21.642.506 | 855.435 | 0,46% | Ações |
| Invesco Ltd. | $20.504.689 | 810.462 | 0,44% | Ações |
| PRINCIPAL FINANCIAL GROUP INC | $19.966.658 | 789.196 | 0,43% | Ações |
| Bank of New York Mellon Corp | $19.243.919 | 760.629 | 0,41% | Ações |
| Allianz Asset Management GmbH | $19.157.034 | 757.195 | 0,41% | Ações |
| PANAGORA ASSET MANAGEMENT INC | $17.985.922 | 710.906 | 0,39% | Ações |
| Fisher Asset Management, LLC | $17.690.535 | 699.230 | 0,38% | Ações |
| FRED ALGER MANAGEMENT, LLC | $16.409.858 | 648.611 | 0,35% | Ações |
| RICE HALL JAMES & ASSOCIATES, LLC | $15.657.841 | 618.887 | 0,34% | Ações |
| AMERIPRISE FINANCIAL INC | $15.348.144 | 606.536 | 0,33% | Ações |
| MILLENNIUM MANAGEMENT LLC | $14.925.077 | 589.924 | 0,32% | Ações |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $14.771.456 | 583.852 | 0,32% | Ações |
| AQR CAPITAL MANAGEMENT LLC | $13.225.551 | 522.749 | 0,28% | Ações |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $12.903.000 | 510.000 | 0,28% | Ações |
| GLENMEDE TRUST CO NA | $12.360.212 | 488.546 | 0,27% | Ações |
| Hudson Bay Capital Management LP | $11.764.500 | 465.000 | 0,25% | Ações |
| UBS Group AG | $11.639.341 | 460.053 | 0,25% | Ações |
| JUPITER ASSET MANAGEMENT LTD | $11.599.190 | 458.466 | 0,25% | Ações |
Ativistas e proprietários de 5%+ 6 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker, FBB3 LLC ×14 declarações | 26 de Fevereiro de 2026 | 25,40% | Emenda | · | SEC |
| Baker Bros. Advisors, LLC, Felix J. Baker, Julian C. Baker ×4 declarações | 6 de Junho de 2013 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 2 de Maio de 2005 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 2 de Maio de 2005 | · | Declaração inicial | · | SEC |
| Pessoa de relato não divulgada, Pessoa de relato não divulgada, Pessoa de relato não divulgada | 2 de Maio de 2005 | · | Declaração inicial | · | SEC |
| Oxford Bioscience Partners IV L.P., mRNA Fund II L.P., OBP Management IV L.P., Jeffrey T. Barnes, Mark P. Carthy, Jonathan J. Fleming, Michael E. Lytton, Alan G. Walton | 29 de Abril de 2005 | · | Declaração inicial | Investimento passivo | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Executivos da empresa 42 insiders · 24 diretores · 21 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Adams Catherine Owen | Chief Executive Officer | 24 de Março de 2026 M | 14.803 | 0 | 1 | $-249.932 |
| Stephen Davis | CEO | 19 de Agosto de 2024 S | 186.555 | 0 | 0 | $0 |
| Uli Hacksell | CEO | 17 de Fevereiro de 2015 M | 115.549 | 0 | 0 | $0 |
| Mark C. Schneyer | EVP, CHIEF FINANCIAL OFFICER | 6 de Agosto de 2026 M | 67.828 | 0 | 9 | $-1.126.027 |
| Elena Ridloff | EVP and CFO | 29 de Abril de 2021 M | 10.553 | 0 | 0 | $0 |
| Todd S. Young | EVP AND CFO | 15 de Outubro de 2018 A | · | 0 | 0 | $0 |
| Thomas H Aasen | EXEC VP, CFO AND CBO | 4 de Abril de 2014 M | 0 | 0 | 0 | $0 |
| Srdjan R. Stankovic | President | 21 de Novembro de 2022 M | 61.234 | 0 | 0 | $0 |
| Mark R Brann | President & CSO | 16 de Junho de 2006 S | 317.756 | 0 | 0 | $0 |
| Brendan Teehan | EVP, COO, HEAD OF COMMERCIAL | 17 de Novembro de 2024 M | 62.105 | 0 | 0 | $0 |
| Elizabeth H.Z. Thompson | EVP, Head of Research & Dev | 29 de Julho de 2026 M | 18.994 | 0 | 3 | $-506.411 |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER | 26 de Junho de 2026 S | 13.088 | 0 | 8 | $-602.789 |
| Jennifer J Rhodes | EVP, CHIEF LEGAL OFFICER, SEC | 24 de Março de 2026 M | 11.280 | 0 | 2 | $-245.022 |
| Thomas Garner | EVP, Chief Commercial Officer | 6 de Março de 2026 A | · | 0 | 0 | $0 |
| Austin D. Kim | EVP,General Counsel, Secretary | 6 de Janeiro de 2024 M | 46.901 | 0 | 0 | $0 |
| Douglas J Williamson | Executive VP, Research & Dev | 10 de Fevereiro de 2023 A | · | 0 | 0 | $0 |
| Michael J. Yang | EVP and CCO | 6 de Janeiro de 2021 M | 8.059 | 0 | 0 | $0 |
| Eric Alejandro Miller | Controller & PAO | 15 de Outubro de 2019 M | 270 | 0 | 0 | $0 |
| Glenn Baity | EVP AND GC | 18 de Abril de 2018 A | 83.734 | 0 | 0 | $0 |
| Terrence O Moore | EVP, CHIEF COMMERCIAL OFFICER | 8 de Março de 2017 A | 1.671 | 0 | 0 | $0 |
| Roger Mills | EVP, DEVELOPMENT AND CMO | 20 de Março de 2015 A | 18.550 | 0 | 0 | $0 |
| Bo-Ragnar Tolf | VP/Mg. Dir. ACADIA Pharma AB | 8 de Julho de 2009 M | 20.000 | 0 | 0 | $0 |
| Brian Lundstrom | Sr. VP, Bus. Development | 7 de Março de 2008 A | 0 | 0 | 0 | $0 |
| Robert E Davis | Exec. VP, Drug Discovery | 11 de Março de 2005 A | · | 0 | 0 | $0 |
| Adora Ndu | Conselheiro | 29 de Maio de 2026 A | 32.908 | 0 | 0 | $0 |
| Elizabeth A. Garofalo | Conselheiro | 29 de Maio de 2026 A | 33.489 | 0 | 0 | $0 |
| Jonathan Poole | Conselheiro | 29 de Maio de 2026 A | 2.010 | 0 | 0 | $0 |
| James M Daly | Conselheiro | 29 de Maio de 2026 A | 12.148 | 0 | 1 | $-671.100 |
| Laura Brege | Conselheiro | 29 de Maio de 2026 A | 23.202 | 0 | 0 | $0 |
| Edmund Harrigan | Conselheiro | 29 de Maio de 2026 A | 43.148 | 0 | 0 | $0 |
| Daniel B Soland | Conselheiro | 29 de Maio de 2025 A | 44.041 | 0 | 0 | $0 |
| Mary Ann Gray | Conselheiro | 7 de Junho de 2016 M | 149.476 | 0 | 0 | $0 |
| Leslie L Iversen | Conselheiro | 18 de Abril de 2016 M | 36.127 | 0 | 0 | $0 |
| Lester J Ph D Kaplan | Conselheiro | 11 de Agosto de 2015 M | 17.000 | 0 | 0 | $0 |
| William Mcdowall Wells | Conselheiro | 15 de Junho de 2015 A | 0 | 0 | 0 | $0 |
| Torsten Rasmussen | Conselheiro | 15 de Junho de 2015 A | 8.500 | 0 | 0 | $0 |
| Michael T Borer | Conselheiro | 15 de Junho de 2015 A | 0 | 0 | 0 | $0 |
| Gordon M Binder | Conselheiro | 12 de Junho de 2009 A | 14.364 | 0 | 0 | $0 |
| Alan G Walton | Conselheiro | 12 de Junho de 2009 A | 25.979 | 0 | 0 | $0 |
| Martien Van Osch | Conselheiro | 10 de Junho de 2005 A | 1.168.892 | 0 | 0 | $0 |
| GORDON CARL L | Conselheiro | 20 de Abril de 2005 A | 774.006 | 0 | 0 | $0 |
| John Joseph Kaiser | · | 20 de Outubro de 2008 A | · | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Participação em ETFs Detido por 59 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.
| Fundo | Peso | Unidades | Em | Fonte |
|---|---|---|---|---|
| IBRN · iShares Trust | 4,92% | 13.265 SH | 11 de Setembro de 2026 | Diário |
| PBE · Invesco Exchange-Traded Fund Trust | 1,82% | 383.853 SH | 1 de Outubro de 2026 | Diário |
| BBP · ETFis Series Trust I | 1,69% | 64.350 NS | 31 de Julho de 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 1,40% | 124.236 SH | 1 de Outubro de 2026 | Diário |
| RZG · Invesco Exchange-Traded Fund Trust | 0,97% | 57.480 SH | 1 de Outubro de 2026 | Diário |
| LABU · Direxion Shares ETF Trust | 0,71% | 134.777 NS | 31 de Julho de 2026 | N-PORT |
| ROSC · Lattice Strategies Trust | 0,62% | 14.725 NS | 31 de Julho de 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,35% | 150.827 SH | 19 de Agosto de 2026 | Diário |
| IBB · iShares Trust | 0,35% | 1.293.913 SH | 11 de Setembro de 2026 | Diário |
| IWO · iShares Trust | 0,24% | 1.215.092 SH | 11 de Setembro de 2026 | Diário |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,23% | 12.181 SH | 1 de Outubro de 2026 | Diário |
| PWS · Pacer Funds Trust | 0,20% | 1.841 NS | 31 de Julho de 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,19% | 137.860 SH | 19 de Agosto de 2026 | Diário |
| BKSE · BNY Mellon ETF Trust | 0,19% | 6.256 NS | 31 de Julho de 2026 | N-PORT |
| QVMS · Invesco Exchange-Traded Fund Trust … | 0,17% | 19.976 SH | 1 de Outubro de 2026 | Diário |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,17% | 443.221 SH | 19 de Agosto de 2026 | Diário |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,16% | 36.279 NS | 31 de Julho de 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,13% | 34.493 NS | 31 de Julho de 2026 | N-PORT |
| IWM · iShares Trust | 0,12% | 3.296.450 SH | 11 de Setembro de 2026 | Diário |
| ISCG · iShares Trust | 0,12% | 40.348 SH | 11 de Setembro de 2026 | Diário |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,11% | 140.676 SH | 1 de Outubro de 2026 | Diário |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,10% | 741.237 SH | 19 de Agosto de 2026 | Diário |
| DFAS · Dimensional ETF Trust | 0,09% | 559.090 NS | 31 de Julho de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,09% | 1.699.377 SH | 19 de Agosto de 2026 | Diário |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,08% | 40.712 NS | 31 de Julho de 2026 | N-PORT |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,05% | 52.423 SH | 1 de Outubro de 2026 | Diário |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,05% | 10.893 NS | 31 de Julho de 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,05% | 2.295 NS | 31 de Julho de 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,04% | 54.681 NS | 31 de Julho de 2026 | N-PORT |
| IEUS · iShares Trust | 0,04% | 7.263 SH | 11 de Setembro de 2026 | Diário |
| VXF · VANGUARD INDEX FUNDS | 0,04% | 1.457.036 SH | 19 de Agosto de 2026 | Diário |
| VB · VANGUARD INDEX FUNDS | 0,04% | 2.944.095 SH | 19 de Agosto de 2026 | Diário |
| VHT · VANGUARD WORLD FUND | 0,04% | 346.329 SH | 19 de Agosto de 2026 | Diário |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,04% | 13.154 SH | 1 de Outubro de 2026 | Diário |
| WSML · iShares Trust | 0,04% | 11.751 SH | 11 de Setembro de 2026 | Diário |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,03% | 4.009 SH | 1 de Outubro de 2026 | Diário |
| DXUV · Dimensional ETF Trust | 0,02% | 5.018 NS | 31 de Julho de 2026 | N-PORT |
| ISCF · iShares Trust | 0,02% | 13.099 SH | 11 de Setembro de 2026 | Diário |
| DFUV · Dimensional ETF Trust | 0,02% | 113.182 NS | 31 de Julho de 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,02% | 348.929 NS | 31 de Julho de 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0,02% | 103.974 NS | 31 de Julho de 2026 | N-PORT |
| SCZ · iShares Trust | 0,02% | 238.968 SH | 9 de Setembro de 2026 | Diário |
| DCOR · Dimensional ETF Trust | 0,01% | 16.150 NS | 31 de Julho de 2026 | N-PORT |
| ESGV · VANGUARD WORLD FUND | 0,01% | 28.150 SH | 19 de Agosto de 2026 | Diário |
| DFAU · Dimensional ETF Trust | 0,01% | 39.121 NS | 31 de Julho de 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 35.516 SH | 10 de Setembro de 2026 | Diário |
| ITOT · iShares Trust | 0,00% | 161.527 SH | 11 de Setembro de 2026 | Diário |
| DFUS · Dimensional ETF Trust | 0,00% | 35.634 NS | 31 de Julho de 2026 | N-PORT |
| IEFA · iShares Trust | 0,00% | 240.578 SH | 11 de Setembro de 2026 | Diário |
| TILT · FlexShares Trust | 0,00% | 632 NS | 31 de Julho de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4.075.731 SH | 19 de Agosto de 2026 | Diário |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,00% | 100.076 SH | 19 de Agosto de 2026 | Diário |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 10.781 SH | 19 de Agosto de 2026 | Diário |
| IJR · iShares Trust | · | 7.728.763 SH | 10 de Setembro de 2026 | Diário |
| IJT · iShares Trust | · | 1.198.794 SH | 9 de Setembro de 2026 | Diário |
| XJR · iShares Trust | · | 17.544 SH | 31 de Agosto de 2026 | Diário |
| ISCB · iShares Trust | · | 5.636 SH | 11 de Setembro de 2026 | Diário |
| SMLF · iShares Trust | · | 221.806 SH | 11 de Setembro de 2026 | Diário |
| SMMV · iShares Trust | · | 16.924 SH | 19 de Agosto de 2026 | Diário |
ACAD Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
classificação · 27 analistas
COMPRA
Alvo mediano
$33.00
+65,4%
7 25,9%
Compra forte
14 51,9%
Compra
5 18,5%
Manter
1 3,7%
Venda
0 0,0%
Venda forte
Preço-alvo de 12 meses
19 analistas · 2026-09-29Alvo médio $32.16 +61,2%
Agora
Preço atual $19.95
Mín$17.00
Média$32.16
Máx$49.00
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | · |
| IDYA | $3.04B | -27.0 | 3024.4% | -52.0% | -11.5% | · |
| VCYT | $3.34B | 51.3 | 16.0% | 12.8% | 5.2% | 70.1% |
| CELC | $4.81B | -26.3 | · | · | -244.3% | · |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | · |
| DNLI | $2.58B | -5.6 | 204.7% | · | -50.2% | · |
| RCUS | $2.99B | -7.2 | -4.3% | -142.9% | -59.8% | · |
| ARQT | $3.58B | -223.4 | 91.3% | -4.3% | -9.8% | · |
| PGEN | $1.48B | -3.1 | 146.7% | -2588.2% | 3159.1% | · |
| PURR | $1.58B | 2.5 | · | 3229.8% | 24.8% | · |
| DYN | $3.23B | -5.6 | · | · | -57.8% | · |
Últimas notícias Notícias recentes mencionando esta empresa
Sinais de trading Sinais recentes de compra/venda com preço de entrada e relação risco/recompensa
BLUECHIP_DIP
Expirado
risco 1
recompensa 5,00
entrada
$21.20
R:R 5,00
BLUECHIP_DIP
Stop out
risco 1
recompensa 4,79
entrada
$21.86
R:R 4,79
BLUECHIP_DIP
Stop out
risco 1
recompensa 4,99
entrada
$22.45
R:R 4,99
Nenhum sinal aberto no momento — nenhum cartão está preenchido, e isso é honesto.
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Fonte: SEC 10-Q arquivado Ago 5, 2026